EP Patent

EP1421078B1 — Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes

Assigned to Eli Lilly and Co · Expires 2006-09-27 · 20y expired

What this patent protects

The present invention relates to a beta3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity

USPTO Abstract

The present invention relates to a beta3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity

Drugs covered by this patent

Patent Metadata

Patent number
EP1421078B1
Jurisdiction
EP
Classification
—
Expires
2006-09-27
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.